A new class of RNA molecules called adaptamers could give clinicians dynamic control over therapeutic protein levels in gene therapy.

Researchers have developed a technology that uses small-molecule drugs to control when cells produce therapeutic proteins, potentially making gene therapies safer and more adaptable for treating chronic diseases.
Developed by bioengineers at the University of California San Diego, the approach could help overcome a key challenge in gene therapy by maintaining therapeutic protein production without allowing levels to become excessively high or remain elevated for too long.
In preclinical studies, the researchers used the technology to activate production of a protein that promoted weight loss, improved blood sugar regulation and almost completely reversed fat accumulation in the liver.
A drug-controlled switch for gene therapy
One of the challenges with gene therapy is that cells can continue producing a therapeutic protein long after the genetic instructions have been delivered. This can be problematic when a protein is only beneficial at certain levels, as too much or prolonged production can lead to unwanted side effects.
To give researchers greater control over this process, the team developed a technology called adaptamers, short for ADAR-modulatable aptamers.
Created by researchers in the laboratory of Prashant Mali, Professor of Bioengineering at the University of California San Diego, adaptamers are short RNA molecules that use small-molecule drugs to regulate protein production.
When an activating drug binds to an adaptamer, it triggers a natural cellular process that allows cells to read genetic instructions and produce the desired protein. Changing the amount of drug administered can influence protein production, while stopping the drug allows production to decrease without removing the gene therapy itself.
This could give clinicians greater flexibility to adjust treatment as a patient’s needs change.
“They could increase the dose of the drug to the point where the desired therapeutic effect is seen, then reduce the dose or stop giving the patient the drug if protein levels become too high, side effects emerge, or the gene therapy is no longer needed,” explained study first author Jack Bryant, a bioengineering PhD student in Mali’s research group.
Reversing metabolic disease in preclinical studies
To demonstrate the technology’s potential, the researchers engineered adaptamers to control production of fibroblast growth factor 21 (FGF21), which helps regulate metabolism and has attracted interest as a potential treatment for obesity.
The team used small-molecule drugs, including tetracycline and doxycycline, to activate FGF21 production. Although the protein can promote weight loss and improve metabolic health, excessive or prolonged exposure can contribute to muscle loss and reduced bone density. This makes controlling its production critical when exploring its therapeutic potential.
In their preclinical experiments, activating FGF21 production resulted in substantial weight loss and improved blood sugar regulation. The researchers also observed an almost complete reversal of fat accumulation in the liver.
These results show how drug-controlled protein production could help manage the effects of therapeutic proteins while retaining their potential benefits.
Expanding the technology
The researchers now plan to refine the adaptamer system for other applications, including gene therapies targeting the brain that could be switched on and off as required.
They also aim to explore safer ways of delivering molecules that encourage damaged tissues to repair themselves.
Although further work will be needed to establish how precisely protein production can be controlled and whether the approach is safe and effective in humans, the technology offers a potential route towards more adaptable gene therapies for chronic diseases.



No comments yet